Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PER2 | O15055 | 1/20 | 0.42 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.42 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982155 | 0.84 | GBA1 (0.65) | GBA1GRIA4 | |
| SCHEMBL5188431 | 0.82 | POLB (0.47) | GBA1KEAP1GRIA4POLBPER2 | |
| SCHEMBL390242 | 0.82 | GBA1 (0.46) | GBA1GRIA4POLB | |
| SCHEMBL4986251 | 0.80 | GBA1 (1.00) | GBA1KEAP1 | |
| SCHEMBL4984120 | 0.80 | GBA1 (0.59) | GBA1GRIA4AOC3 | |
| SCHEMBL3432045 | 0.78 | KDM4E (0.57) | PER2CRY1CRY2AOC3 | |
| SCHEMBL17793729 | 0.78 | GRIA4 (0.47) | GBA1KEAP1GRIA4POLBPER2 | |
| SCHEMBL1714980 | 0.77 | GBA1 (0.41) | GBA1KEAP1GRIA4POLBPER2 | |
| SCHEMBL12879312 | 0.77 | GBA1 (0.79) | GBA1 | |
| SCHEMBL4986451 | 0.77 | GBA1 (0.79) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | GBA1 426/4885KEAP1 3377/4885GRIA4 4068/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | GBA1 426/4885KEAP1 3377/4885GRIA4 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.